Paul has been leading scientific progress at Oxford Drug Design after an extensive career at Pfizer, Smithkline Beecham (GSK) and TopoTarget. His expertise extends over drug discovery and early pharmaceutical development. At TopoTarget, where he was Director of R&D, Paul led the preclinical development Beleodaq®, of which he is also an inventor, used to treat patients with peripheral T-cell lymphoma. At Oxford Drug Design he has led our computational drug discovery platform as well as our drug discovery efforts and has been instrumental in the raising of c. £10M of non-dilutive finance internationally. Paul studied biochemistry at the University of Oxford and obtained his PhD at the University of Manchester. He is a Professorial Research Fellow at the University of Buckingham School of Computer Science, working at the interface of drug discovery and machine learning.
Contributing Author
Disclaimer: All opinions, ideas, and thoughts expressed and posted by Contributors at BiopharmaTrend.com platform are their own personal points of view, and do not represent neither Contributor's employers, nor BiopharmaTrend.com.
